Microbotox: A prospective evaluation of dermatological improvement in patients with mild‐to‐moderate acne and erythematotelangiectatic rosacea

Abstract Background Botulin toxin (BTX) is a potent neurotoxin produced by the bacterium Clostridium botulinum, since its approval by FDA in 2002 for cosmetic purpose has been widely used. Recent studies indicate that it exerts its activity on various type of skin cells and can be used in some dermatological disease. Objective The aim of the study was to demonstrate how to use a peculiar dilution of botulinum toxin type A in the treatment of some dermatological disease like mild‐to‐moderate acne vulgaris and erythematotelangiectatic rosacea. Material and Methods 50 patients were enrolled, 35 with mild‐to‐moderate acne and 15 with erythematotelangiectatic rosacea. Both group of patients were treated with a specific dilution of Onabotulinum toxin A called Microbotox. Patient images were taken before and 4 weeks after the treatment. Results The authors and patients were extremely satisfied with their treatments. There were no immediate or delayed complication in none of both group of patients. Conclusion Botulinum toxin shows a great promise either in dermatological disease like mild‐to‐moderate acne vulgaris and erythematotelangiectatic rosacea. Microbotox appears to be a valid, long‐lasting, and a standardized approach to treat these kind of two disease.